Tolerability of multiple administration of intramuscular meloxicam: A comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis

British Journal of Rheumatology

Volumn 35, Issue SUPPL. 1, 1996, Pages 51-55

  Ghozlan, P R ^a   Bernhardt, M ^b   Velicitat P ^c   Bluhmki, E ^c  

^a Polyclinique D'Aubervilliers   (France)

^b Kurklinikam Park   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Creatinine phosphokinase; Intramuscular; Meloxicam; Non steroidal anti inflammatory drugs; Osteoarthritis; Piroxicam; Rheumatoid arthritis; Tolerability

Indexed keywords

CREATINE KINASE; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; OSTEOARTHRITIS; OTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; URINARY TRACT DISEASE;

EID: 0029960260     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.suppl_1.51     Document Type: Article

References (15)

1. Patoia L, Santucci L, Furno P et al. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptoms evaluation in healthy volunteers. Br J Rheumatol 1995;35(suppl. 1):61-7.
2. Lund B, Distel M, Bluhmki E. A double-blind, placebo controlled study of three different doses of meloxicam in patients with osteoarthritis (OA) of the knee. Scand J Rheumatol 1994;Suppl 98:abstract no. 117.
3. Lindén B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 1995; 35(suppl. 1):35-8.
4. Lemmel EM, Bolten W, Burgos-Vargas R et al. A double-blind placebo controlled study of 7.5 mg and 15 mg of meloxicam in patients with rheumatoid arthritis (RA). Scand J Rheumatol 1994;Suppl 98:abstract no. 111.
5. Huskisson EC, Narjes H, Bluhmki E. Efficacy and tolerance of meloxicam, a new NSAID, in daily oral doses of 15, 30 and 60 mg in comparison to 20 mg piroxicam in patients with rheumatoid arthritis. Scand J Rheumatol 1994;Suppl 98:abstract no. 115.
6. Narjes H, Türck D, Busch U, Heinzel G, Nehmiz G. Tolerability and pharmacokinetics of meloxicam after i.m. administration. Br J Clin Pharmacol 1996;41:135-40
7. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
8. Altman R, Alarcow G, Appeirouth D et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505-14.
9. Altman R, Asch E, Bloch D et al. Development of criteria for the classification and reporting of osteoarthritis. Arthritis Rheum 1986;29:1039-49.
10. Eandi M, Buraglio M, Casilli D et al. Injectable piroxicam in acute musculoskeletal disorders: results of a large multicentre study. Curr Ther Res 1989;45:381-97.
11. Svendsen O, Rasmussen F, Nielsen P, Steiness E. The loss of creatinine kinase (CK) from intramuscular injections sites in rabbits. A predictive toll for local toxicity. Acta Pharmacol Toxicol 1979;44:324-8.
12. Cingolani E, Cingolani G, Mosconi P, Coppi G. Local tolerance evaluation of intramuscular drug preparations. II Farmaco Ed Pr 1986;41:89-97.
13. Vaccarino V, Sirtori CR, Bufalino L. Local and systemic tolerability of piroxicam after intramuscular administration in healthy volunteers. Curr Ther Res 1989;45:1-13.
14. Cacace L. Elevated serum CPK after drug injections. N Engl J Med 1972;287:309-10.
15. Stei P, Kruss B, Wiegleb J, Trach V. Local tissue tolerability of meloxicam, a new NSAID: indications for parenteral, dermal and mucosal administration. Br J Rheumatol 1996;35(suppl. 1):44-50.